Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

Abcam Company

ABC.L
GB00B6774699
A1C605

Price

12.26
Today +/-
+0
Today %
+0 %
P

Abcam stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Abcam stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Abcam stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Abcam stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Abcam's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Abcam Stock Price History

DateAbcam Price
12/13/202212.26 undefined
12/12/202211.03 undefined

Abcam Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Abcam, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Abcam from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Abcam’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Abcam. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Abcam’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Abcam’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Abcam’s growth potential.

Abcam Revenue, EBIT and net profit per share

DateAbcam RevenueAbcam EBITAbcam Net Income
2026e615.41 M undefined214.31 M undefined164.27 M undefined
2025e545.23 M undefined166.51 M undefined129.48 M undefined
2025e475.19 M undefined0 undefined228.92 M undefined
2024e509.86 M undefined149.47 M undefined108.91 M undefined
2023e453.03 M undefined118.42 M undefined86.73 M undefined
2022e398.46 M undefined80.53 M undefined69.4 M undefined
2021462.9 M undefined50 M undefined17.2 M undefined
2020297.7 M undefined37.4 M undefined16.2 M undefined
2019260 M undefined35.9 M undefined12.5 M undefined
2018259.9 M undefined77.1 M undefined45 M undefined
2017233.2 M undefined81.3 M undefined62.2 M undefined
2016217.1 M undefined59.57 M undefined42.36 M undefined
2015171.67 M undefined50.27 M undefined37.43 M undefined
2014144.03 M undefined45.73 M undefined37.38 M undefined
2013128 M undefined43.3 M undefined34 M undefined
2012122.2 M undefined42.8 M undefined32.7 M undefined
201197.8 M undefined34.2 M undefined25.4 M undefined
201083.3 M undefined31.7 M undefined23.8 M undefined
200971.1 M undefined25.6 M undefined19.2 M undefined
200856.8 M undefined17.2 M undefined12.3 M undefined
200736.7 M undefined7.4 M undefined5.9 M undefined
200624.5 M undefined5.2 M undefined4.1 M undefined
200519.4 M undefined4.6 M undefined3.7 M undefined
200412.1 M undefined2.9 M undefined2.3 M undefined
20036.7 M undefined1.4 M undefined1 M undefined
20023.5 M undefined600,000 undefined500,000 undefined

Abcam Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200220032004200520062007200820092010201120122013201420152016201720182019202020212022e2023e2024e2025e2025e2026e
361219243656718397122128144171217233259260297462398453509475545615
-100.00100.0058.3326.3250.0055.5626.7916.9016.8725.774.9212.5018.7526.907.3711.160.3914.2355.56-13.8513.8212.36-6.6814.7412.84
66.6766.6758.3357.8958.3361.1166.0766.2067.4769.0770.4970.3170.1470.1870.0569.9670.6669.2371.0471.21------
247111422374756678690101120152163183180211329000000
0124571725313442434550598177353750801181490166214
-16.6716.6721.0520.8319.4430.3635.2137.3535.0534.4333.5931.2529.2427.1934.7629.7313.4612.4610.8220.1026.0529.27-30.4634.80
01234512192325323437374262451216176986108228129164
--100.0050.0033.3325.00140.0058.3321.058.7028.006.258.82-13.5147.62-27.42-73.3333.336.25305.8824.6425.58111.11-43.4227.13
172.1172.1172.1165.3177.6177.9179.8182.9183.4188.5199.9200201.28202204.22205.8206.7209.6226226.3000000
--------------------------
Details

Keystats

Revenue and Growth

The Abcam Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Abcam is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20022003200420052006200720082009201020112012201320142015201620172018201920202021
                                       
0.21.11.511.910.714.525.540.255.618.23956.557.7471.4685.7490.287.1187.3219.995.1
0.40.91.72.43.33.75.46.87.91011.512.113.2319.5921.9524.929.331.446.433.2
0.10.10.20.410.50.50.60.92.74.62.44.125.564.156.414.114.76.919.4
0.20.61.22.43.14.56.89.110.715.415.314.819.819.6821.7629.63640.745.958.2
000000.71.91.71.32.41.95.15.643.379.868.85.34.70.65.6
0.92.74.617.118.123.940.158.476.448.772.390.9100.52119.65143.46159.9171.8278.8319.7211.5
0.30.20.81.12.84.23.52.92.55.87.58.512.4517.6222.3225.137.1164.7160161.7
0000000000000000.90.873.53.5
00000000000000000000
0000.11.710.80.62.134.333.130.244.8270.2173.59106.3106.7154.4155.2234.2
000000002.182.48273.585.2112.46115.51114.2120.9192.8181364.8
0000000.71.53.54.653.46.969.626.818.49.413.75.110.4
0.30.20.81.24.55.25510.2127.1127.6115.6149.42209.91218.23254.9274.9532.6504.8774.6
1.22.95.418.322.629.145.163.486.6175.8199.9206.5249.95329.56361.7414.8446.7811.4824.5986.1
                                       
000300300400400400400400400400402405409400400400500500
0.811.610.610.610.911.612.915.471.872.917.719.5221.5523.9125.627138.2265.5268.3
-0.10.61.64.17.512.923.739.959.576.297.7172.8196.5225.68258.4302.5328.2324.3350.8358.2
0000001.10.7-0.21.41.2-7.80.4916.7928.0326.43242.220.231.3
00000000000000000000
0.71.63.21518.424.236.853.975.1149.8172.2183.1216.92264.42310.75354.9387.6505.1637658.3
0.20.40.81.21.421.72.63.54.14.83.74.674.246.87779.457.112.9
0.20.30.91.21.41.94.84.14.868.89.59.3114.8120.3624.532.731.9031.1
00.50.40.70.60.923.43.74.54.43.67.0814.245.3717.55.64.61.714.8
00000000000000000106.40119.2
000000000000000007.38.19.2
0.41.22.13.13.44.88.510.11214.61816.821.0633.2932.64945.3159.666.9187.2
00000000000000000120.5102.4101.3
000000.1000.412.911.38.814.7822.9421.881416.528.720.541.5
000.10.10.80.10.10.20.200.400.0112.140.10.10.1000
000.10.10.80.20.10.20.612.911.78.814.7835.0821.9814.116.6149.2122.9142.8
0.41.22.23.24.258.610.312.627.529.725.635.8468.3754.5863.161.9308.8189.8330
1.12.85.418.222.629.245.464.287.7177.3201.9208.7252.76332.79365.32418449.5813.9826.8988.3
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Abcam provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Abcam's financial health and stability.

Assets

Abcam's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Abcam must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Abcam after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Abcam's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2003200420052006200720082009201020112012201320142015201620172018201920202021
124571525313442434545516856102824
00001111256811151215293557
0000000000000000000
0-1,000-2,000-2,000-2,000-4,000-8,000-8,000-13,000-10,000-9,000-16,000-12,000-5,000-17,000-18,0001,000-5,000-12,000
00001111110234016211327
0000000000000000123
0001125781198910913259
112371419252439414047666370637196
000-4-2-20-1-2-7-7-7-15-19-37-40-35-57-84
000-4-2-10-3-53-7-6-24-21-33-37-49-148-45-313
0000000-2-5001-17-5-130-9-11211-229
0000000000000000000
00-102-11-230200000000100-1150
0090000000011111111127130
00-11-2-1-27-710-11-13-14-15-17-20-241848126
----------------1.00-1.00-2.00-4.00
0-1-10-1-2-5-7-10-12-14-15-16-19-22-24-2500
0001212-814-172119111155-310032-92
1.011.082.21-0.244.4212.7918.8424.2921.6332.2133.8232.7331.7347.2125.929.827.314.711.9
0000000000000000000

Abcam stock margins

The Abcam margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Abcam. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Abcam.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Abcam's sales revenue. A higher gross margin percentage indicates that the Abcam retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Abcam's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Abcam's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Abcam's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Abcam. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Abcam's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Abcam Margin History

Abcam Gross marginAbcam Profit marginAbcam EBIT marginAbcam Profit margin
2026e71.12 %34.82 %26.69 %
2025e71.12 %30.54 %23.75 %
2025e71.12 %0 %48.18 %
2024e71.12 %29.32 %21.36 %
2023e71.12 %26.14 %19.14 %
2022e71.12 %20.21 %17.42 %
202171.12 %10.8 %3.72 %
202071.15 %12.56 %5.44 %
201969.31 %13.81 %4.81 %
201870.49 %29.67 %17.31 %
201769.9 %34.86 %26.67 %
201670.06 %27.44 %19.51 %
201570.21 %29.28 %21.8 %
201470.49 %31.75 %25.96 %
201370.63 %33.83 %26.56 %
201270.95 %35.02 %26.76 %
201169.12 %34.97 %25.97 %
201067.23 %38.06 %28.57 %
200966.67 %36.01 %27 %
200865.85 %30.28 %21.65 %
200760.76 %20.16 %16.08 %
200659.18 %21.22 %16.73 %
200561.34 %23.71 %19.07 %
200461.98 %23.97 %19.01 %
200362.69 %20.9 %14.93 %
200260 %17.14 %14.29 %

Abcam Stock Sales Revenue, EBIT, Earnings per Share

The Abcam earnings per share therefore indicates how much revenue Abcam has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Abcam earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Abcam's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Abcam’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Abcam's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Abcam Revenue, EBIT and net profit per share

DateAbcam Sales per ShareAbcam EBIT per shareAbcam Earnings per Share
2026e2.69 undefined0 undefined0.72 undefined
2025e2.38 undefined0 undefined0.57 undefined
2025e2.08 undefined0 undefined1 undefined
2024e2.23 undefined0 undefined0.48 undefined
2023e1.98 undefined0 undefined0.38 undefined
2022e1.74 undefined0 undefined0.3 undefined
20212.05 undefined0.22 undefined0.08 undefined
20201.32 undefined0.17 undefined0.07 undefined
20191.24 undefined0.17 undefined0.06 undefined
20181.26 undefined0.37 undefined0.22 undefined
20171.13 undefined0.4 undefined0.3 undefined
20161.06 undefined0.29 undefined0.21 undefined
20150.85 undefined0.25 undefined0.19 undefined
20140.72 undefined0.23 undefined0.19 undefined
20130.64 undefined0.22 undefined0.17 undefined
20120.61 undefined0.21 undefined0.16 undefined
20110.52 undefined0.18 undefined0.13 undefined
20100.45 undefined0.17 undefined0.13 undefined
20090.39 undefined0.14 undefined0.1 undefined
20080.32 undefined0.1 undefined0.07 undefined
20070.21 undefined0.04 undefined0.03 undefined
20060.14 undefined0.03 undefined0.02 undefined
20050.12 undefined0.03 undefined0.02 undefined
20040.07 undefined0.02 undefined0.01 undefined
20030.04 undefined0.01 undefined0.01 undefined
20020.02 undefined0 undefined0 undefined

Abcam business model

Abcam PLC is an internationally operating company specializing in the development, manufacturing, and distribution of antibodies and other reagents for life science research. History: Abcam was founded in 1998 by Jonathan Milner, a biologist and cancer researcher who had experienced using antibodies in research. Recognizing a need for high-quality and reliable reagents in this field, he decided to start his own company. In the years following its founding, Abcam grew rapidly and established itself as one of the leading providers of antibodies. In 2005, the company went public on the London Stock Exchange, raising capital for further expansion. Since then, Abcam has made numerous acquisitions and expanded its product portfolio. Business model: Abcam's business model is based on selling antibodies and other reagents to research institutions, universities, and pharmaceutical companies. The company relies on an extensive network of suppliers and partners to offer a wide range of products. Another important aspect of the business model is the online marketing of Abcam's products. The company operates several websites where customers can browse and order the entire product range. To better understand customer needs, Abcam also conducts regular customer surveys and feedback. Divisions: Abcam offers a wide range of products and services, which are grouped into various divisions: Antibodies: The antibodies division is Abcam's core area, encompassing a variety of monoclonal and polyclonal antibodies for various applications. Proteins: Abcam also offers a wide range of proteins for research in areas such as cancer, neurology, and metabolic diseases. Reagents: In addition to antibodies and proteins, Abcam provides a variety of reagents, including kits for biomarker or enzyme activity determination. Services: Abcam also offers a range of services, including custom antibody development, protein expression, and assay development. Products: Abcam offers a wide range of products for use in various areas of life science research. Some of the most well-known products include: Rabbit monoclonal antibodies: These antibodies are highly specific and sensitive, making them valuable tools in cancer research. Chromatin & nucleic acid purification kits: These kits enable efficient purification of DNA, RNA, and chromatin, which is essential for many genomic and epigenomic applications. ELISA kits: Abcam offers a variety of ELISA kits for the determination of biomarkers and other target molecules. Overall, Abcam is a leading provider of antibodies and other reagents for life science research. Through constant innovation and expansion, the company has successfully grown its business in recent years and is now well-positioned worldwide. Abcam is one of the most popular companies on Eulerpool.com.

Abcam SWOT Analysis

Strengths

Abcam PLC has a strong reputation in the life sciences industry as a leading provider of high-quality research antibodies and other biological tools.

The company has a diverse and extensive product portfolio, offering a wide range of antibodies, kits, proteins, and other reagents, which caters to the needs of various research areas.

Abcam PLC has established a global presence with a strong network of distributors, enabling it to serve customers in different regions effectively.

Weaknesses

The company heavily relies on the market demand for research antibodies, which is subject to fluctuations and competition from other manufacturers, potentially impacting sales and profitability.

Abcam PLC's success is influenced by the ability to consistently develop and introduce innovative products, as failure to do so may result in losing market share to competitors.

Opportunities

The increasing focus on personalized medicine and targeted therapeutics presents an opportunity for Abcam PLC to develop and offer customized research tools to support these advancements.

Expanding into emerging markets, such as Asia-Pacific and Latin America, can provide Abcam PLC with access to a rapidly growing customer base and potential new revenue streams.

Threats

The potential emergence of alternative technologies or platforms for research purposes could disrupt the demand for traditional antibodies and affect Abcam PLC's market position.

Intense competition within the life sciences industry poses a threat to Abcam PLC's market share, as other companies may offer similar products at competitive prices.

Abcam Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Abcam historical P/E ratio, EBIT multiple, and P/S ratio

Abcam shares outstanding

The number of shares was Abcam in 2023 — This indicates how many shares 226.3 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Abcam earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Abcam's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Abcam’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Abcam's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Abcam dividend history and estimates

In 2023, Abcam paid a dividend amounting to 0.34 GBP. Dividend means that Abcam distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Abcam provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Abcam’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Abcam's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Abcam Dividend History

DateAbcam Dividend
2026e0.74 undefined
2025e0.57 undefined
2025e1.05 undefined
2024e0.5 undefined
2023e0.34 undefined
2022e0.36 undefined
20200.04 undefined
20190.12 undefined
20180.12 undefined
20170.1 undefined
20160.09 undefined
20150.09 undefined
20140.09 undefined
20130.08 undefined
20120.07 undefined
20110.06 undefined
20100.04 undefined
20090.03 undefined
20080.01 undefined
20070.01 undefined
20060.01 undefined

Abcam dividend payout ratio

In 2023, Abcam had a payout ratio of 90.91%. The payout ratio indicates the percentage of the company's profits that Abcam distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Abcam represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Abcam could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Abcam's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Abcam Payout Ratio History

DateAbcam Payout ratio
2026e103.02 %
2025e99.99 %
2025e104.75 %
2024e104.31 %
2023e90.91 %
2022e119.03 %
2021102.99 %
202050.71 %
2019203.39 %
201854.88 %
201733.93 %
201642.96 %
201549.23 %
201446.36 %
201346.01 %
201242.01 %
201144.87 %
201034.24 %
200924.46 %
200817.78 %
200729.56 %
200630 %
2005102.99 %
2004102.99 %
2003102.99 %
2002102.99 %
Unfortunately, there are currently no price targets and forecasts available for Abcam.

Abcam latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20220.15 0.14  (-4.31 %)2022 Q2
12/31/20210.08 0.28  (256.6 %)2021 Q4
6/30/20210.09 0.05  (-47.66 %)2021 Q2
1

Abcam shareholders

%
Name
Stocks
Change
Date
9.28510 % T. Rowe Price Associates, Inc.21,255,68703/14/2022
7.94603 % Milner (Jonathan Simon)18,190,2562,462,13012/31/2021
6.86017 % Miller (Danielle)15,704,46603/14/2022
6.74527 % Harding Loevner LP15,441,44003/14/2022
6.33351 % Baillie Gifford & Co.14,498,81803/14/2022
5.82682 % Durable Capital Partners LP13,338,89803/14/2022
3.64243 % Brown Capital Management, LLC8,338,34303/14/2022
3.33794 % Wasatch Global Investors Inc7,641,29203/14/2022
1.89630 % Liontrust Investment Partners LLP4,341,058-1,846,8157/29/2022
1.87138 % T. Rowe Price International Ltd4,284,002-50,2447/26/2022
1
2
3
4
5
...
10

Abcam Executives and Management Board

Mr. Alan Hirzel54
Abcam Chief Executive Officer, Executive Director (since 2013)
Compensation 3.79 M
Mr. Michael Baldock58
Abcam Chief Financial Officer, Executive Director (since 2020)
Compensation 1.33 M
Ms. Mara Aspinall59
Abcam Non-Executive Independent Director
Compensation 95,527
Mr. Giles Kerr62
Abcam Senior Non-Executive Independent Director
Compensation 89,433
Mr. Mark Capone59
Abcam Non-Executive Independent Director
Compensation 76,028
1
2

Abcam Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,790,320,46-0,28-0,40-0,45
NanoString Technologies Stock
NanoString Technologies
SupplierCustomer0,440,67-0,080,610,180,43
SupplierCustomer0,340,840,440,910,670,53
SupplierCustomer0,070,87-0,070,830,470,59
SupplierCustomer-0,060,730,250,880,40-
SupplierCustomer-0,120,320,230,860,690,45
SupplierCustomer-0,130,570,750,680,560,55
SupplierCustomer-0,79-0,330,490,700,370,44
SupplierCustomer-0,83-0,650,370,84--
1

Most common questions regarding Abcam

What values and corporate philosophy does Abcam represent?

Abcam PLC represents a strong set of values and corporate philosophy. As a global leader in the supply of life science research tools, Abcam is committed to enabling scientific discoveries and improving human health. Their values include innovation, collaboration, integrity, and customer focus. Abcam fosters a culture of excellence, empowering their employees to make a positive impact. With their customer-centric approach, Abcam strives to provide high-quality products and exceptional service to researchers worldwide. By upholding these values and embodying their corporate philosophy, Abcam PLC continues to make significant contributions to the scientific community and drive advancements in the field of life sciences.

In which countries and regions is Abcam primarily present?

Abcam PLC is primarily present in multiple countries and regions around the world. Its global presence includes the United Kingdom, the United States, China, Japan, Germany, France, and Australia, among others. Abcam PLC has established a strong presence in these regions through its extensive network of distributors, sales offices, and research collaborations. With a global footprint, Abcam PLC efficiently serves its customers, scientists, and researchers worldwide, providing them with innovative and high-quality research tools and reagents to support their scientific endeavors.

What significant milestones has the company Abcam achieved?

Abcam PLC, a leading provider of life science research tools, has achieved several significant milestones. Over the years, the company has expanded its product portfolio, establishing a comprehensive range of high-quality antibodies, proteins, assays, and reagents. Abcam PLC has also formed numerous collaborations with renowned academic and clinical institutions, enabling innovative research discoveries. The company's commitment to quality and innovation has led to the development of key technologies, including RabMAb® antibodies, which offer superior specificity and sensitivity. Moreover, Abcam PLC has successfully expanded its global presence, with offices and distribution centers across major research hubs worldwide. These milestones validate Abcam PLC's position as a trusted partner in advancing scientific knowledge.

What is the history and background of the company Abcam?

Abcam PLC is a renowned life sciences company based in the United Kingdom. Established in 1998, Abcam has emerged as a global leader in the supply of research tools to the scientific community. With a focus on providing high-quality antibodies, proteins, and other essential reagents, Abcam has developed a vast product portfolio catering to various research areas, including cancer, neuroscience, and immunology. The company's commitment to innovation and quality has enabled it to forge strong partnerships with academic institutions and biopharmaceutical companies worldwide. Abcam's dedication to advancing scientific knowledge and supporting researchers has solidified its position as a prominent player in the life sciences industry.

Who are the main competitors of Abcam in the market?

The main competitors of Abcam PLC in the market include Thermo Fisher Scientific, Merck KGaA, and Bio-Rad Laboratories.

In which industries is Abcam primarily active?

Abcam PLC is primarily active in the life sciences industry. As a leading provider of research tools, the company specializes in the production and distribution of high-quality antibodies, proteins, and other biological reagents. Abcam PLC serves a diverse range of sectors within the life sciences field, including academia, pharmaceuticals, biotechnology, and clinical diagnostics. With its broad portfolio of products and global presence, Abcam PLC supports scientists and researchers worldwide in their quest for breakthrough discoveries and advancements in various areas such as cancer research, neuroscience, stem cells, immunology, and more.

What is the business model of Abcam?

The business model of Abcam PLC is focused on the production and distribution of high-quality antibodies and other life science research tools. Abcam works closely with academic and industrial researchers worldwide to provide essential reagents needed for conducting experiments and advancing scientific discoveries in the fields of genomics, proteomics, and immunology. By offering a broad range of products, including primary and secondary antibodies, proteins, peptides, and assays, Abcam aims to support researchers in their quest for better understanding and treatment of diseases. Through its online platform and global distribution network, Abcam ensures that its products reach scientists efficiently, enabling them to accelerate their research and make meaningful contributions to their respective fields.

What is the P/E ratio of Abcam 2024?

The Abcam P/E ratio is 25.47.

What is the P/S ratio of Abcam 2024?

The Abcam P/S ratio is 5.44.

What is the Quality Investing of Abcam?

The Quality Investing for Abcam is 4/10.

What is the revenue of Abcam 2024?

The expected Abcam revenue is 509.86 M GBP.

How high is the profit of Abcam 2024?

The expected Abcam profit is 108.91 M GBP.

What is the business model of Abcam

Abcam PLC is a company specializing in the development and marketing of antibodies and other research reagents. The company was founded in 1998 and is headquartered in Cambridge, UK. It has branches in several countries, including the US, China, and Japan. Abcam offers its customers a wide range of products and services focused on immunology, cell biology, epigenetics, and neurobiology. The company is divided into two business areas: research products and diagnostics. Under the research products category, Abcam offers a wide range of antibodies, proteins, kits, and reagents used by scientists and researchers worldwide. The company offers over 130,000 antibodies focusing on a variety of research areas. Additionally, the company provides a variety of resources and tools on its website, such as data sheets, protocols, and videos, to help researchers make their work more effective. Abcam's diagnostics division includes a wide range of products and services aimed at improving disease diagnosis and finding therapeutic solutions. The company's advanced technologies include innovative proteomics and epitope mapping tools, as well as cutting-edge platforms for developing immunassays. Abcam strives to offer its customers the best products and services. For this reason, the company has implemented strict quality controls and tests to ensure that all products meet the highest standards. The company also offers a 100% satisfaction guarantee and provides free replacement products or refunds if customers are not satisfied with their purchases. Abcam is also actively involved in nonprofit research. The company has established the Abcam Research Awards, which allow scientists to receive financial support for their groundbreaking research. Abcam's business model is focused on meeting customer needs while promoting the company's growth. The company aims to maintain its position as a leading provider of antibodies and other research reagents and expand into new areas such as diagnostics and therapeutics. It relies on a solid infrastructure, qualified employees, and strategic partnerships to successfully serve its customers. In summary, Abcam is a leading provider of research products and diagnostics focusing on immunology, cell biology, epigenetics, and neurobiology. The company offers its customers a wide range of products and services centered around strict quality controls and tests, as well as a 100% satisfaction guarantee. Abcam's business model is focused on innovation, offering high-quality products and services, and meeting customer needs.

What is the Abcam dividend?

Abcam pays a dividend of 0 GBP distributed over payouts per year.

How often does Abcam pay dividends?

The dividend cannot currently be calculated for Abcam or the company does not pay out a dividend.

What is the Abcam ISIN?

The ISIN of Abcam is GB00B6774699.

What is the Abcam WKN?

The WKN of Abcam is A1C605.

What is the Abcam ticker?

The ticker of Abcam is ABC.L.

How much dividend does Abcam pay?

Over the past 12 months, Abcam paid a dividend of 0.04 GBP . This corresponds to a dividend yield of about 0.29 %. For the coming 12 months, Abcam is expected to pay a dividend of 1.05 GBP.

What is the dividend yield of Abcam?

The current dividend yield of Abcam is 0.29 %.

When does Abcam pay dividends?

Abcam pays a quarterly dividend. This is distributed in the months of December, April, December, April.

How secure is the dividend of Abcam?

Abcam paid dividends every year for the past 6 years.

What is the dividend of Abcam?

For the upcoming 12 months, dividends amounting to 1.05 GBP are expected. This corresponds to a dividend yield of 8.54 %.

In which sector is Abcam located?

Abcam is assigned to the 'Health' sector.

Wann musste ich die Aktien von Abcam kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Abcam from 4/17/2020 amounting to 0.036 GBP, you needed to have the stock in your portfolio before the ex-date on 3/19/2020.

When did Abcam pay the last dividend?

The last dividend was paid out on 4/17/2020.

What was the dividend of Abcam in the year 2023?

In the year 2023, Abcam distributed 0.361 GBP as dividends.

In which currency does Abcam pay out the dividend?

The dividends of Abcam are distributed in GBP.

All fundamentals about Abcam

Our stock analysis for Abcam Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abcam Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.